AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31376501 — intervention group
Group type: COMPARATOR
Intervention: Wait List (WL) condition
Number of subjects: 0
Study 30971158 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulvertaft repair with three weaves
Number of subjects: 45
Study 30971158 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Pulvertaft repair
Number of subjects: 45
Study 30971158 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking Pulvertaft repair
Number of subjects: 45
Study 30971158 — intervention group
Group type: COMPARATOR
Intervention: Traditional Pulvertaft weave
Number of subjects: 45
Study 29191593 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab plus docetaxel
Number of subjects: 360
Study 29191593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 25987078 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (Endostar) 7.5 mg/m2, administered on postoperative day 89, 34 h/time, daily, for 14 weeks, total of 4 cycles
Number of subjects: 75
Study 25987078 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human endostatin (Endostar)
Number of subjects: 75
Study 25987078 — intervention group
Group type: COMPARATOR
Intervention: Control group received postoperative complementary chemotherapy containing two-agent platinum protocol
Number of subjects: 75
Study 23328488 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal approach
Number of subjects: 120
Study 23328488 — intervention group
Group type: COMPARATOR
Intervention: Subinguinal approach
Number of subjects: 120
Study 21439754 — intervention group
Group type: EXPERIMENTAL
Intervention: CAC scanning
Number of subjects: 2137
Study 21439754 — intervention group
Group type: COMPARATOR
Intervention: No CAC scanning
Number of subjects: 2137
Study 19435759 — intervention group
Group type: EXPERIMENTAL
Intervention: Downton Index (IG)
Number of subjects: 1125
Study 19435759 — intervention group
Group type: COMPARATOR
Intervention: No tool used (CG)
Number of subjects: 1125
Study 16758412 — intervention group
Group type: EXPERIMENTAL
Intervention: PnCRM7
Number of subjects: 749
Study 16758412 — intervention group
Group type: COMPARATOR
Intervention: Group C meningococcal conjugate vaccine
Number of subjects: 749
Study 15234136 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin applied 4 times a day for 3 days before surgery
Number of subjects: 75
Study 15234136 — intervention group
Group type: COMPARATOR
Intervention: Topical ofloxacin applied 1 hour before surgery (control group)
Number of subjects: 75
Study 11402115 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa (300/75 mg/d)
Number of subjects: 30
Study 11402115 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (1.5 mg/d)
Number of subjects: 30
Study 11402115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9431265 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Nerve Stimulation (ENS) therapy
Number of subjects: 60
Study 9431265 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation (EMS) therapy
Number of subjects: 60
Study 9431265 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (control group)
Number of subjects: 60
Study 7818046 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiant heater (group R, n = 11)
Number of subjects: 35
Study 7818046 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air system (group B, n = 12)
Number of subjects: 35
Study 7818046 — intervention group
Group type: COMPARATOR
Intervention: Normal cotton hospital blanket (group K, n = 12)
Number of subjects: 35
Study 3045049 — intervention group
Group type: EXPERIMENTAL
Intervention: ceftizoxime
Number of subjects: 114
Study 3045049 — intervention group
Group type: COMPARATOR
Intervention: cefotaxime
Number of subjects: 114
Study 31127755 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) treatment - 4-ml PRP intra-articularly (IA) in three doses at one-week intervals
Number of subjects: 60
Study 31127755 — intervention group
Group type: COMPARATOR
Intervention: Saline solution - 4-ml saline solution IA (control group)
Number of subjects: 60
Study 31334544 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT group (6 g/d of medium-chain triglycerides)
Number of subjects: 64
Study 31334544 — intervention group
Group type: COMPARATOR
Intervention: LD + MCT group (1.2 g l-leucine, 20 μg cholecalciferol, 6 g/d MCTs)
Number of subjects: 64
Study 31334544 — intervention group
Group type: COMPARATOR
Intervention: LCT group (6 g/d of long-chain triglycerides)
Number of subjects: 64
Study 30645864 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat-containing canned food for enteral nutrition (240 ml, 2 portions daily for 14 days)
Number of subjects: 40
Study 28644183 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 767
Study 28644183 — intervention group
Group type: EXPERIMENTAL
Intervention: Mercaptopurine (MP)
Number of subjects: 767
Study 23475103 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) pre-treatment for 4 days prior to chemotherapy
Number of subjects: 56
Study 23475103 — intervention group
Group type: COMPARATOR
Intervention: No Dexamethasone (no DEX)
Number of subjects: 56
Study 21126771 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma
Number of subjects: 23
Study 21126771 — intervention group
Group type: EXPERIMENTAL
Intervention: Autosomal‐dominant optic atrophy (ADOA)
Number of subjects: 23
Study 21126771 — intervention group
Group type: EXPERIMENTAL
Intervention: Leber's hereditary optic neuropathy (LHON)
Number of subjects: 23
Study 21126771 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal controls
Number of subjects: 23
Study 21126771 — intervention group
Group type: COMPARATOR
Intervention: Pathologic but nonglaucomatous discs
Number of subjects: 23
Study 21126771 — intervention group
Group type: COMPARATOR
Intervention: Normal discs
Number of subjects: 23
Study 21126771 — intervention group
Group type: EXPERIMENTAL
Intervention: Pallor assessment in glaucomatous discs
Number of subjects: 23
Study 19595605 — intervention group
Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 120
Study 19595605 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (conventional haemostatic fleece)
Number of subjects: 120
Study 17621464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential pegylated interferon‐α2a plus delayed‐initiation tenofovir
Number of subjects: 0
Study 17621464 — intervention group
Group type: COMPARATOR
Intervention: Dual nucleoside/nucleotide suppression
Number of subjects: 0
Study 14685799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 0
Study 14685799 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 14685799 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 14685799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11698879 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management booklet
Number of subjects: 311
Study 11698879 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to take regular exercise
Number of subjects: 311
Study 11698879 — intervention group
Group type: EXPERIMENTAL
Intervention: Both booklet and exercise advice
Number of subjects: 311
Study 11698879 — intervention group
Group type: COMPARATOR
Intervention: Control group (neither intervention)
Number of subjects: 311
Study 9446401 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation in patients with relative contraindications
Number of subjects: 51
Study 9446401 — intervention group
Group type: COMPARATOR
Intervention: Control group of 413 patients without relative contraindications
Number of subjects: 51
Study 7947854 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (received a Gerry 'Cuddler' for returning for examination within 12 weeks of delivery)
Number of subjects: 240
Study 7947854 — intervention group
Group type: COMPARATOR
Intervention: Non-incentive group (no incentive offered)
Number of subjects: 240
Study 2850807 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (15-30 g per day)
Number of subjects: 23
Study 2850807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31859172 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Children Through Individual Vouchers Evaluation intervention (activity vouchers of £20 per month, peer mentoring scheme, support worker engagement for 12 months)
Number of subjects: 909
Study 31859172 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Children Through Individual Vouchers Evaluation intervention
Number of subjects: 909
Study 31859172 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 909
Study 29435911 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based intervention (16 calls over 3 months)
Number of subjects: 100
Study 29435911 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 100
Study 27509050 — intervention group
Group type: EXPERIMENTAL
Intervention: LRM (n = 17): 3 sets of 4-6 RM
Number of subjects: 45
Study 27509050 — intervention group
Group type: EXPERIMENTAL
Intervention: HRM (n = 16): 3 sets of 12-15 RM
Number of subjects: 45
Study 27509050 — intervention group
Group type: COMPARATOR
Intervention: Control (CON, n = 12)
Number of subjects: 45
Study 24150927 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ceftaroline fosamil 1,500 mg with avibactam 2,000 mg
Number of subjects: 51
Study 24150927 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ceftazidime 3,000 mg with avibactam 2,000 mg
Number of subjects: 51
Study 24150927 — intervention group
Group type: COMPARATOR
Intervention: Oral moxifloxacin 400 mg (open-label positive control)
Number of subjects: 51
Study 24150927 — intervention group
Group type: COMPARATOR
Intervention: IV placebo (saline)
Number of subjects: 51
Study 21920502 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 30
Study 21920502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20811582 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid receptor antagonist naloxone
Number of subjects: 0
Study 18267008 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 2755
Study 18267008 — intervention group
Group type: COMPARATOR
Intervention: Conventional wound therapy
Number of subjects: 2755
Study 16835758 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated Oka strain varicella vaccine (Varilrix, GlaxoSmithKline Biologicals)
Number of subjects: 160
Study 12590879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injection of hyaluronans
Number of subjects: 0
Study 12590879 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronans
Number of subjects: 0
Study 10773631 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV, Fluor Protector) containing 0.1% F, treated every 3rd month for 3 years (12 treatments total)
Number of subjects: 180
Study 10773631 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine varnish (CV, Cervitec) containing 1% chlorhexidine and 1% thymol, treated every 3rd month for 3 years (12 treatments total)
Number of subjects: 180
Study 8809428 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 20 mg
Number of subjects: 26
Study 8809428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8338403 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 10
Study 8338403 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 10
Study 3436485 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron protein succinylate (80 mg Fe3+)
Number of subjects: 0
Study 3436485 — intervention group
Group type: COMPARATOR
Intervention: Ferritin (80 mg Fe3+)
Number of subjects: 0
Study 30045094 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with 40% unloading
Number of subjects: 10
Study 30045094 — intervention group
Group type: COMPARATOR
Intervention: Pressure support
Number of subjects: 10
Study 30045094 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with 60% unloading
Number of subjects: 10
Study 26875428 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate-guided beta-blocker titration
Number of subjects: 100
Study 26875428 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker uptitration
Number of subjects: 100
Study 24894577 — intervention group
Group type: EXPERIMENTAL
Intervention: High level of positive end-expiratory pressure (12 cm H2O) with recruitment manoeuvres
Number of subjects: 900
Study 24894577 — intervention group
Group type: COMPARATOR
Intervention: Low level of positive end-expiratory pressure (≤2 cm H2O) without recruitment manoeuvres
Number of subjects: 900
Study 24894577 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PEEP group
Number of subjects: 900
Study 24894577 — intervention group
Group type: COMPARATOR
Intervention: Lower PEEP group
Number of subjects: 900
Study 23541564 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus everolimus (5mg p.o. daily, after a step-wise dose-escalation starting from 2.5mg bid) for 12 weeks before surgery
Number of subjects: 403
Study 23541564 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (80 mg/m(2) weekly for 12 weeks)
Number of subjects: 403
Study 23541564 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus everolimus
Number of subjects: 403
Study 23541564 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 403
Study 20510986 — intervention group
Group type: EXPERIMENTAL
Intervention: STTotal‐11
Number of subjects: 43
Study 20510986 — intervention group
Group type: EXPERIMENTAL
Intervention: STUp‐11
Number of subjects: 43
Study 20510986 — intervention group
Group type: EXPERIMENTAL
Intervention: STTotal‐11 and STUp‐11
Number of subjects: 43
Study 18091017 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate-electrolyte (CHO-E) solution
Number of subjects: 6
Study 18091017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 6
Study 15915277 — intervention group
Group type: EXPERIMENTAL
Intervention: Support of a healthcare practitioner and a family member
Number of subjects: 0
Study 12931800 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation system during total knee arthroplasty
Number of subjects: 240
Study 12931800 — intervention group
Group type: COMPARATOR
Intervention: Hand-guided technique
Number of subjects: 240
Study 11014761 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental conditions with varying parameters (seat height, pedal travel, pedal travel inclination, pedal resistance)
Number of subjects: 15
Study 11014761 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedal resistance and pedal travel
Number of subjects: 15
Study 8970358 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm NO2 for 4 h
Number of subjects: 44
Study 1461553 — intervention group
Group type: EXPERIMENTAL
Intervention: nimesulide (200 mg/day)
Number of subjects: 40
Study 1461553 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 3984360 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention addressing urinary tract infections, its risk factors, and behavioral changes
Number of subjects: 34
Study 3984360 — intervention group
Group type: COMPARATOR
Intervention: Routine patient information provided by practitioners
Number of subjects: 34
Study 30096200 — intervention group
Group type: EXPERIMENTAL
Intervention: FSMS-RUTF
Number of subjects: 0
Study 30096200 — intervention group
Group type: EXPERIMENTAL
Intervention: MSMS-RUTF
Number of subjects: 0
Study 30096200 — intervention group
Group type: COMPARATOR
Intervention: PM-RUTF
Number of subjects: 0
Study 27499311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (40 mg/day women, 160 mg/day men) and high energy oral nutritional supplement (2108-2416 kJ/day)
Number of subjects: 53
Study 27499311 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication and low energy (142-191 kJ/day) 'placebo' oral nutritional supplementation
Number of subjects: 53
Study 27499311 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate and nutritional supplementation
Number of subjects: 53
Study 24907147 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN + MTX
Number of subjects: 723
Study 24907147 — intervention group
Group type: COMPARATOR
Intervention: csDMARD + MTX
Number of subjects: 723
Study 22434018 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing augmentation device
Number of subjects: 192
Study 22434018 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hearing augmentation)
Number of subjects: 192
Study 20616774 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-containing nutritional supplement (9 g per day until full PU healing)
Number of subjects: 18
Study 20616774 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (no specific intervention mentioned)
Number of subjects: 18
Study 20616774 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation for category 2 PU
Number of subjects: 18
Study 20616774 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation for category 3 PU
Number of subjects: 18
Study 20616774 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation for category 4 PU
Number of subjects: 18
Study 18534138 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-blood cardioplegia (insulin and glucose added)
Number of subjects: 24
Study 18534138 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia (control group)
Number of subjects: 24
Study 18534138 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-blood cardioplegia
Number of subjects: 24
Study 16474301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxyphylline
Number of subjects: 0
Study 12433835 — intervention group
Group type: EXPERIMENTAL
Intervention: HuEP5C7 (20 mg/kg IV)
Number of subjects: 18
Study 12433835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 9949357 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone
Number of subjects: 0
Study 9949357 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 0
Study 7585494 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam brush soaked in chlorhexidine
Number of subjects: 0
Study 7585494 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush
Number of subjects: 0
Study 7585494 — intervention group
Group type: COMPARATOR
Intervention: Foam brush (not soaked in chlorhexidine)
Number of subjects: 0
Study 2202920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin 100 ng/ml and prednisone (0.15 mg/kg/day)
Number of subjects: 94
Study 2202920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin 50 ng/ml, prednisone (0.15 mg/kg/day), and azathioprine (1 mg/kg/day)
Number of subjects: 94
Study 2202920 — intervention group
Group type: COMPARATOR
Intervention: Prednisone and azathioprine (control group)
Number of subjects: 94
Study 6449783 — intervention group
Group type: EXPERIMENTAL
Intervention: IK-6 (combination of fenoterol and ipratropium bromide)
Number of subjects: 22
Study 6449783 — intervention group
Group type: EXPERIMENTAL
Intervention: IK-6
Number of subjects: 22
Study 6449783 — intervention group
Group type: EXPERIMENTAL
Intervention: IK-6 (20 puffs)
Number of subjects: 22
Study 6449783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (20 puffs)
Number of subjects: 22
Study 6449783 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide (20 puffs)
Number of subjects: 22
Study 6449783 — intervention group
Group type: COMPARATOR
Intervention: Oxitropium bromide (20 puffs)
Number of subjects: 22
Study 6449783 — intervention group
Group type: COMPARATOR
Intervention: Dibenzothiepine-derivative (20 puffs)
Number of subjects: 22
Study 31434537 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-Extremity Intensive Functional Training (LIFT)
Number of subjects: 24
Study 31434537 — intervention group
Group type: COMPARATOR
Intervention: Hand-Arm Bimanual Intensive Therapy (H-HABIT)
Number of subjects: 24
Study 28241715 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture repair group (40 patients)
Number of subjects: 91
Study 28241715 — intervention group
Group type: COMPARATOR
Intervention: Control group (33 patients)
Number of subjects: 91
Study 28241715 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture repair group
Number of subjects: 91
Study 28241715 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study 26163644 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm I: Irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions, weekly cisplatin 40 mg/m2, HDR-ICBT after one week of completion of EBRT (7 Gy to point A for three insertions at one week intervals)
Number of subjects: 50
Study 26163644 — intervention group
Group type: COMPARATOR
Intervention: Arm II: Irradiation of the whole pelvis to a dose of 50 Gy in 27 fractions, cisplatin 20 mg/m2/day from D1‐5 and D24‐28, HDR-ICBT after 40Gy (7 Gy to point A for three insertions on days 23, 30, 37)
Number of subjects: 50
Study 24261438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of paracetamol, chlorphenamine and phenylephrine (5 capsules per day for 48 to 72 hours)
Number of subjects: 146
Study 24261438 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 capsules per day for 48 to 72 hours)
Number of subjects: 146
Study 20663642 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior-stabilized (PS) TKA
Number of subjects: 40
Study 20663642 — intervention group
Group type: EXPERIMENTAL
Intervention: Cruciate-retaining (CR) TKA
Number of subjects: 40
Study 19952576 — intervention group
Group type: EXPERIMENTAL
Intervention: Unstable resistance training
Number of subjects: 40
Study 19952576 — intervention group
Group type: COMPARATOR
Intervention: Stable resistance training
Number of subjects: 40
Study 17449194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pretreatment EBV DNA (<1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-L/post-U)
Number of subjects: 152
Study 17449194 — intervention group
Group type: EXPERIMENTAL
Intervention: High pretreatment EBV DNA (>=1,500 copies/mL) and undetectable posttreatment EBV DNA (pre-H/post-U)
Number of subjects: 152
Study 17449194 — intervention group
Group type: EXPERIMENTAL
Intervention: Low or high pretreatment EBV DNA and detectable posttreatment EBV DNA (pre-L or H/post-D)
Number of subjects: 152